Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis

The use of anthracyclines such as doxorubicin (DOX) has improved outcome in cancer patients, yet associated risks of cardiomyopathy have limited their clinical application. DOX-associated cardiotoxicity is frequently irreversible and typically progresses to heart failure (HF) but our understanding o...

Descripción completa

Detalles Bibliográficos
Autores principales: Roca-Alonso, L, Castellano, L, Mills, A, Dabrowska, A F, Sikkel, M B, Pellegrino, L, Jacob, J, Frampton, A E, Krell, J, Coombes, R C, Harding, S E, Lyon, A R, Stebbing, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669718/
https://www.ncbi.nlm.nih.gov/pubmed/25950484
http://dx.doi.org/10.1038/cddis.2015.89

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669718/
https://www.ncbi.nlm.nih.gov/pubmed/25950484
http://dx.doi.org/10.1038/cddis.2015.89

Ejemplares similares